SCHEMBL1597410

SCHEMBL1597410

CC(C)(C)OC(=O)N1CCCN(C(=O)c2ccc(/C=C/c3n[nH]c4ccccc34)cc2)CC1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK10 P53779 7/20 0.66
FLT3 P36888 6/20 0.66
MAPK8 P45983 4/20 0.66
ABL1 P00519 2/20 0.66
CHEK1 O14757 2/20 0.66
KDR P35968 2/20 0.66
BMPR1B O00238 1/20 0.66
PLK4 O00444 1/20 0.66
STK25 O00506 1/20 0.66
CIT O14578 1/20 0.66
RIOK3 O14730 1/20 0.66
IKBKB O14920 1/20 0.66
AURKA O14965 1/20 0.66
GAK O14976 1/20 0.66
DCLK1 O15075 1/20 0.66
CHUK O15111 1/20 0.66
MUSK O15146 1/20 0.66
EPHB6 O15197 1/20 0.66
PDPK1 O15530 1/20 0.66
MAP3K13 O43283 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1597412 1.00 MAPK10 (0.66) MAPK10FLT3MAPK8ABL1CHEK1
SCHEMBL1595848 0.97 MAPK10 (0.70) MAPK10FLT3MAPK8ABL1CHEK1
SCHEMBL1595850 0.97 MAPK10 (0.70) MAPK10FLT3MAPK8ABL1CHEK1
Hydrochloric Acid SCHEMBL1597513 0.85 MAPK10 (0.72) MAPK10FLT3MAPK8ABL1CHEK1
Hydrochloric Acid SCHEMBL1597517 0.85 MAPK10 (0.72) MAPK10FLT3MAPK8ABL1CHEK1
SCHEMBL1596330 0.85 MAPK10 (0.54) MAPK10FLT3MAPK8ABL1CHEK1
SCHEMBL1597183 0.85 MAPK10 (0.64) MAPK10FLT3MAPK8ABL1CHEK1
SCHEMBL1597187 0.85 MAPK10 (0.64) MAPK10FLT3MAPK8ABL1CHEK1
SCHEMBL1596328 0.85 MAPK10 (0.54) MAPK10FLT3MAPK8ABL1CHEK1
SCHEMBL1596379 0.85 MAPK10 (0.75) MAPK10FLT3MAPK8ABL1CHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7919517-B2 Indazole derivatives KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-04-05 US disclosed
US-20090082348-A1 INDAZOLE DERIVATIVES KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-03-26 US disclosed
US-7470717-B2 Indazole derivatives KYOWA HAKKO KOGYO CO., LTD. (JP) 2008-12-30 US disclosed
US-20070117856-A1 Indazole derivatives KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-05-24 US disclosed
EP-1652842-A1 INDAZOLE DERIVATIVES KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-05-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070117856-A1 Indazole derivatives IGF1R, NR0B2, ADRA2B MAPK10 2823/4885FLT3 684/4885MAPK8 2117/4885
US-20090082348-A1 INDAZOLE DERIVATIVES IGF1R, NR0B2, ADRA2B MAPK10 2823/4885FLT3 684/4885MAPK8 2117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.